x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Foundation Fighting Blindness

Foundation Fighting Blindness

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.

science

All Episodes

00:04:26

Opus Reports Vision Improvements for Three Pediatric...

Foundation Fighting Blindness ·

2025/09/30

Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.

en

00:30:52

Eye on the Cure Podcast | Episode 92: Lance Baldo, MD

Foundation Fighting Blindness ·

2025/09/26

Lance Baldo, MD, CEO at Beacon Therapeutics, talks to host Ben Shaberman about his company's fully enrolled Phase 3 VISTA clinical trial for laru-zova, a gene therapy for X-linked retinitis pigmentosa (RPGR mutations) that's showed promising results in earlier trials. They also discuss Beacon's forthcoming clinical trial for its dry age-related macular degeneration gene therapy.

en

00:02:57

Agnes Gund – Renowned Philanthropist, Social Justice...

Foundation Fighting Blindness ·

2025/09/22

The documentary “Aggie: An Incredible Story of Art and Justice” chronicles her story.

en

00:03:37

Nacuity’s Antioxidative Therapy NACA Performs...

Foundation Fighting Blindness ·

2025/09/12

NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.

en

00:22:19

Eye on the Cure Podcast | Episode 91: Dr. George Magrath

Foundation Fighting Blindness ·

2025/09/05

September 5, 2025. Dr. George Magrath, CEO of Opus Genetics, talks with host Ben Shaberman about the company's evolution and progress in clinically developing gene therapies for several inherited retinal diseases including those caused by mutations in the genes: LCA5, BEST1, RHO, RDH12, MERTK, NMNAT1, and CNGB1.

en

00:02:07

Opus Genetics Receives FDA Clearance to Launch...

Foundation Fighting Blindness ·

2025/08/22

The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.

en

00:03:07

jCyte Launches New Phase 2 Clinical Trial for its...

Foundation Fighting Blindness ·

2025/08/20

The trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.

en

00:27:11

Eye on the Cure Podcast | Episode 90: Dr. Christina...

Foundation Fighting Blindness ·

2025/08/08

August 8, 2025. Dr. Christina Ohnsman talks to host Ben Shaberman about Tern Therapeutics, a start-up company she co-founded to develop gene therapies for Batten disease and potentially other conditions. Dr. Ohnsman reviews early results for a Batten disease (CLN2) retinal gene therapy clinical trial. She also reflects on her previous work as a pediatric ophthalmologist and roles with Spark Therapeutics and Regenxbio.

en

00:03:05

Wet AMD Treatment Susvimo Preserves Vision for Five...

Foundation Fighting Blindness ·

2025/08/06

Susvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule

en

00:37:22

Eye on the Cure Podcast | Episode 89: Dr. Christine...

Foundation Fighting Blindness ·

2025/07/25

July 25, 2025. Dr. Christine Curcio, one of the world's foremost experts in age-related macular degeneration (AMD) pathogenesis and the associated risk of advanced vision loss, talks to host Ben Shaberman about her epical career and recent Proctor Medal lecture with Dr. Cynthia Owsley at the 2025 meeting of the Association for Eye and Vision Research (ARVO). Her work has led to a highly effective test for predicting who is at greatest risk of losing vision from AMD.

en

00:01:43

Ocugen Launches Phase 2/3 Clinical Trial for...

Foundation Fighting Blindness ·

2025/07/21

The therapy delivers copies of the RORA gene to address multiple disease pathways.

en

00:02:48

Nanoscope Begins Rolling BLA Submission to FDA for...

Foundation Fighting Blindness ·

2025/07/14

The company plans to complete BLA submission in early 2026.

en

00:25:47

Eye on the Cure Podcast | Episode 88: Richard Small

Foundation Fighting Blindness ·

2025/07/11

July 11, 2025. Richard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTO™, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The therapy is a tiny, implantable capsule, the size of a rice grain, that delivers neurotrophic factors to preserve the patient's retinal cells and vision. The approach was previously developed to treat retinitis pigmentosa and age-related macular degeneration.

en

00:04:00

Atsena Gets FDA Nod to Expand XLRS Gene Therapy...

Foundation Fighting Blindness ·

2025/07/09

The expanded Phase 1/2/3 shortens time to potential FDA approval.

en

00:18:54

Eye on the Cure Podcast | Episode 87: Dr. Philip Beales

Foundation Fighting Blindness ·

2025/06/13

June 13, 2025. Dr. Philip Beales, a co-founder of Axovia Therapeutics, talks to host Ben Shaberman about Bardet Biedl syndrome, ciliopathies, and his company's emerging gene therapy for Bardet Biedl syndrome type 1 (BBS1) which is moving toward a clinical trial.

en

00:31:15

Eye on the Cure Podcast | Episode 86: Lenore von...

Foundation Fighting Blindness ·

2025/05/23

May 23, 2025. Lenore von Krusenstiern, MD, PhD, at BlueRock Therapeutics talks to host Ben Shaberman about the company's clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy. The approach, which uses induced pluripotent stem cells to develop photoreceptor precursors, comes out of the lab of stem cell pioneer David Gamm, MD, PhD, University of Wisconsin-Madison.

en

00:02:35

J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint...

Foundation Fighting Blindness ·

2025/05/15

Despite missing the primary endpoint, the treatment improved vision for some patients.

en

00:04:53

ARVO 2025 Highlight: PYC Reports Encouraging Phase...

Foundation Fighting Blindness ·

2025/05/13

The company is planning a Phase 2/3 clinical trial for therapy in late 2025.

en

00:04:15

ARVO 2025 Highlight: Atsena’s XLRS Gene Therapy...

Foundation Fighting Blindness ·

2025/05/12

Part B of the trial will enroll nine adult patients as well as three pediatric patients.

en

00:03:07

ARVO 2025 Highlight: Beacon Reports Encouraging...

Foundation Fighting Blindness ·

2025/05/09

The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.

en

252 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter